-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor On March 15, 2022, Sanofi and Blackstone Life Sciences announced a strategic collaboration
.
Under the terms of the collaboration agreement, Blackstone Life Sciences will pay up to €300 million to accelerate a global pivotal research and clinical development program to evaluate a subcutaneous formulation of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma (MM) patients
.
Sanofi will continue to fully manage the clinical program
.
If successful, Blackstone Life Sciences will be eligible to receive royalties on future product sales
.
The pivotal study is expected to begin in the second half of 2022
.
MM is the second most common hematological malignancy, with more than 130,000 new cases diagnosed globally each year
.
Despite available treatments, MM remains an incurable malignancy and is associated with a significant patient burden
.
Since there is no cure for MM, most patients relapse
.
Recurrent MM is when the cancer comes back after treatment or after a period of remission
.
Refractory MM is when the cancer does not respond or no longer responds to treatment
.
Sarclisa is a monoclonal antibody that specifically binds to the CD38 receptor expressed on MM cells
.
It acts through multiple mechanisms of action, including programmed tumor cell death (apoptosis) and immunomodulatory activity
.
CD38 is highly uniformly expressed on the surface of MM cells, making it a potential target for antibody-based therapeutics such as Sarclisa
.
In the development of subcutaneous formulations of Sarclisa, Sanofi has partnered with Enable Injections, an innovator in drug delivery technology, to advance the development of subcutaneous delivery of Sarclisa with the goal of providing a unique patient-centered therapeutic experience
.
To date, Sarclisa has been approved by various national and regional regulatory agencies and is used in combination with drugs such as lenalidomide, bortezomib, pomalidomide and dexamethasone in various The form is used in combination as a combination therapy and is used intravenously to treat certain patients with relapsing MM
.
"This collaboration with Blackstone will accelerate our ability to deliver this subcutaneously administered anti-CD38 antibody to patients, which we believe will provide patients with an innovative treatment that is more convenient," said Dr.
John Reed, Sanofi's global head of research and development
.
References: [1] Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma.
Retrieved March 15, 2022, from https:// releases/2022/2022-03-15-07-00-00-2403030 Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
.
Under the terms of the collaboration agreement, Blackstone Life Sciences will pay up to €300 million to accelerate a global pivotal research and clinical development program to evaluate a subcutaneous formulation of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma (MM) patients
.
Sanofi will continue to fully manage the clinical program
.
If successful, Blackstone Life Sciences will be eligible to receive royalties on future product sales
.
The pivotal study is expected to begin in the second half of 2022
.
MM is the second most common hematological malignancy, with more than 130,000 new cases diagnosed globally each year
.
Despite available treatments, MM remains an incurable malignancy and is associated with a significant patient burden
.
Since there is no cure for MM, most patients relapse
.
Recurrent MM is when the cancer comes back after treatment or after a period of remission
.
Refractory MM is when the cancer does not respond or no longer responds to treatment
.
Sarclisa is a monoclonal antibody that specifically binds to the CD38 receptor expressed on MM cells
.
It acts through multiple mechanisms of action, including programmed tumor cell death (apoptosis) and immunomodulatory activity
.
CD38 is highly uniformly expressed on the surface of MM cells, making it a potential target for antibody-based therapeutics such as Sarclisa
.
In the development of subcutaneous formulations of Sarclisa, Sanofi has partnered with Enable Injections, an innovator in drug delivery technology, to advance the development of subcutaneous delivery of Sarclisa with the goal of providing a unique patient-centered therapeutic experience
.
To date, Sarclisa has been approved by various national and regional regulatory agencies and is used in combination with drugs such as lenalidomide, bortezomib, pomalidomide and dexamethasone in various The form is used in combination as a combination therapy and is used intravenously to treat certain patients with relapsing MM
.
"This collaboration with Blackstone will accelerate our ability to deliver this subcutaneously administered anti-CD38 antibody to patients, which we believe will provide patients with an innovative treatment that is more convenient," said Dr.
John Reed, Sanofi's global head of research and development
.
References: [1] Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma.
Retrieved March 15, 2022, from https:// releases/2022/2022-03-15-07-00-00-2403030 Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
